Key result
Clinical investigation of 75- and 76-year-olds with NT-proBNP ≥900 ng/L and no known heart failure detected new atrial fibrillation in 30% and reduced ejection fraction in 10.8%.
Why the study?
High NT-proBNP levels indicate increased probability of congestive heart failure and AF and poor prognosis, but clinical and echocardiographic characteristics in 75/76-year-olds with NT-proBNP ≥900 ng/L without known CHF or AF needed description.
What are the clinical and echocardiographic characteristics of elderly individuals with screening-detected NT-proBNP ≥900 ng/L without known heart failure or atrial fibrillation?
RCT (n=93)
Randomised to a screening study
What are the clinical and echocardiographic characteristics of elderly individuals with screening-detected NT-proBNP ≥900 ng/L without known heart failure or atrial fibrillation?
Elderly individuals with screening-detected NT-proBNP ≥900 ng/L have a high prevalence of undiagnosed atrial fibrillation and structural heart disease, warranting further clinical investigation.
Answers are grounded in this paper and cite their sources.
May warrant targeted cardiac evaluation in elderly with elevated NT-proBNP; leaves open value of population screening.
Background: High plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) indicate increased probability of congestive heart failure (CHF) and atrial fibrillation (AF) and are associated with poor prognosis. Objective: We aimed to describe the clinical and echocardiographic characteristics of a population of individuals aged 75/76 years old with NT-proBNP ≥900 ng/L without previously known CHF or AF. Methods: All individuals aged 75/76 years in the Stockholm region were randomised to a screening study for AF. Half of them were invited to screening. Of those invited, 49.5% agreed to participate. Individuals with NT-proBNP ≥900 ng/L without known CHF were invited for further clinical evaluation. Results: Among 6315 participants without AF who had NT-proBNP sampled, 102 without previously known CHF had ≥900 ng/L. Of these, 93 completed further clinical investigations. In the population that was clinically investigated, 53% were female, and the median NT-proBNP was 1200 ng/L. New AF was found in 28 (30%). The NT-proBNP value in this group was not significantly different from those where AF was not detected (median 1285 vs 1178 ng/L). Patients with newly detected AF had larger left atrial volume and higher pulmonary artery pressure than those without AF. Preserved left ventricular ejection fraction (≥50%) was found in 86% of the participants, mid-range ejection fraction (40%-49%) in 3.2% and reduced ejection fraction (<40%) in 10.8%. Thirteen patients (14%) had other serious cardiac disorders that required medical attention. Conclusion: Elderly individuals with NT-proBNP levels ≥900 ng/L constitute a population at high cardiovascular risk even in the absence of diagnosed CHF or AF, and therefore merit further investigation.
No takes yet. Share an insight, caveat, or question.
Al‐Khalili et al. (2020) conducted an RCT in Elevated NT-proBNP without known congestive heart failure or atrial fibrillation (n=93). Screening for atrial fibrillation including NT-proBNP measurement vs. No screening was evaluated on Detection of new atrial fibrillation. Clinical investigation of 75- and 76-year-olds with NT-proBNP ≥900 ng/L and no known heart failure detected new atrial fibrillation in 30% and reduced ejection fraction in 10.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: